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Abstract 20 
Influenza viruses unable to express NS1 protein (delNS1) replicate poorly and induce 21 
high amounts of interferon (IFN). They are therefore considered as candidate viruses for 22 
live-attenuated influenza vaccines. Their attenuated replication is generally assumed to 23 
result from the inability to counter the antiviral host response, as delNS1 viruses replicate 24 
efficiently in Vero cells, which lack IFN expression. In this study, delNS1 virus was parallel 25 
passaged on IFN competent MDCK cells, which resulted in two strains that were able to 26 
replicate to high virus titres in MDCK cells due to adaptive mutations in especially the M-27 
gene segment, but also the NP and NS gene segments. Most notable were clustered U-to-C 28 
mutations in the M segment of both strains and clustered A-to-G mutations in the NS 29 
segment of one strain, which presumably resulted from host cell mediated RNA editing. The 30 
M segment mutations in both strains changed the ratio of M1 to M2 expression, probably 31 
by affecting splicing efficiency. In one virus, 2 amino acid substitutions in M1 additionally 32 
enhanced virus replication, possibly through changes in the M1 distribution between the 33 
nucleus and the cytoplasm. Both adapted viruses induced equal levels of IFN as delNS1 34 
virus. These results show that the increased replication of the adapted viruses is not 35 
primarily due to altered IFN induction, but rather related to changes in M1 expression or 36 
localization. The mutations identified in this paper may be used to enhance delNS1 virus 37 
replication for vaccine production. 38 
  39 
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Introduction 40 
The non-structural (NS1) protein of influenza A virus is an antagonist of the cellular 41 
antiviral response. Infection with virus either not encoding NS1 protein (delNS1) or encoding 42 
a truncated NS1 protein results in high levels of type I interferons (IFN) such as IFN-α or IFN-43 
β. Replication of such viruses is attenuated in IFN competent cell lines, indicating that the 44 
NS1 protein is not essential for replication in such hosts (14). In vivo, viruses lacking a fully 45 
functional NS1 protein induce IFN in the absence of detectable virus replication (12), which 46 
are favourable conditions for use as live attenuated vaccines. The local release of IFN and 47 
other cytokines and chemokines appears to be an excellent adjuvant that enhances 48 
production of immunoglobulins and contributes to the activation of dendritic cells required 49 
for antigen presentation (22, 31). DelNS1 candidate vaccines against influenza A and B have 50 
been developed (35, 51) and initial trials in humans showed successful induction of antibody 51 
responses (48). Apart from the use in vaccines, delNS1 viruses also show potential as 52 
oncolytic agent (27) and viral expression vector (50). 53 
NS1 is expressed at high levels directly after infection and facilitates virus replication 54 
in many different ways (reviewed in (15)). Its antiviral properties are focused on reducing 55 
the IFN mediated innate immune response and act at several levels. Cytoplasmic dsRNA and 56 
5’-triphosphate-containing RNA are produced during influenza infection and recognized as 57 
pathogenic patterns by antiviral proteins like retinoic-acid inducible gene I (RIG-I), dsRNA-58 
dependent protein kinase R (PKR) and 2’-5’-oligoadenylatesynthetase (OAS). NS1 binds both 59 
dsRNA and RIG-I, and blocks the activation of PKR and OAS, thereby limiting the onset of 60 
several pathways that lead to IFN induction (31). Other functions of NS1 are inhibition of 61 
cellular pre-mRNA processing (including IFN pre-mRNA) and mRNA nuclear export (15). 62 
Furthermore, NS1 regulates both viral genome replication and translation (49), splicing of M 63 
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segment mRNA (32), nuclear export of viral mRNA (13) and viral ribonucleoprotein (vRNP) 64 
(49), and viral protein synthesis (7, 10). Recently it was found that NS1 binds the human 65 
PAF1 transcription elongation complex (hPAF1C) by a histone-mimicking sequence, thereby 66 
inhibiting the role of hPAF1C in the antiviral response (26). NS1 mRNA is transcribed from 67 
the eighth vRNA segment. It is partially spliced to generate mRNA that encodes the nuclear 68 
export protein (NEP) (15). In the nucleus of infected cells, NEP facilitates the export of the 69 
vRNP complexes containing the viral genome segments to the cytoplasm, where assembly of 70 
the viral components is completed before virus budding takes place (1). Independent from 71 
vRNP export, NEP also regulates viral genome transcription and replication (33). During 72 
development of delNS1 strains it is therefore essential to retain the NEP protein. 73 
In cells and animals with a low or absent IFN response, such as Vero cells, STAT1 or 74 
PKR knock-out mice, delNS1 virus replicates to high titres (8, 14, 20), whereas replication is 75 
attenuated in MDCK cells and other IFN-competent hosts. When Vero cells are externally 76 
stimulated with IFN-α before infection, delNS1 virus replication is however also attenuated 77 
(12). Moreover, delNS1 only replicated efficiently in embryonated chicken eggs younger 78 
than 8 days, when the host immune response is not yet fully developed (43). It is therefore 79 
generally assumed that the inability of delNS1 virus to counter the cellular innate immune 80 
response is the major cause for its attenuated phenotype (31). In addition to the unimpaired 81 
IFN response, the absence of NS1 during influenza virus infection results in enhanced 82 
apoptosis induction (41, 57). Activation of caspases, a group of cysteine proteases that play 83 
an important role in apoptosis, results in cleavage of viral NP protein and thereby limits the 84 
amount of viral protein available for assembly of viral particles (56). The antiviral effect of 85 
apoptosis is therefore believed to contribute to the attenuated replication of delNS1 virus. 86 
Inhibition of the apoptotic response is attributed to both the activation by NS1 of the 87 
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phosphatidylinositol 3-kinase (PI3K)-Akt signalling pathway, which is known to result in an 88 
anti-apoptotic response (9, 55), as well as the inhibition of IFN. IFN sensitizes cells for 89 
apoptosis (57) through its transcriptional induction of PKR (44) and activation of the 90 
FADD/caspase-8 death signalling pathway (4). The role of apoptosis in influenza infection is, 91 
however, still uncertain as several influenza proteins, including NS1, also exhibit pro-92 
apoptotic functions. Furthermore, influenza virus replication is impaired in the presence of 93 
caspase inhibitors (52), which appears to be caused by retention of vRNA complexes in the 94 
nucleus, preventing formation of progeny virus particles. A possible explanation for this 95 
double role of NS1 in apoptosis regulation could be prevention of cell death by inhibition of 96 
apoptosis early in the infection, followed by induction at a later stage (55). Ludwig et al. (24) 97 
suggested that caspases enhance vRNP export from the nucleus later in the infection by 98 
widening of the nuclear pores, thereby allowing diffusion of vRNP out of the nucleus.  99 
Previously we showed that delNS1 virus can efficiently be propagated on a MDCK 100 
cell line showing inducible expression of NS1 from a trans-complementing genomic gene 101 
(46). A 500-fold increase in infectious virus titre was observed, even though the NS1 level 102 
was 1000-fold lower than that in cells infected with wild-type (WT) virus. Furthermore, 103 
apoptosis was reduced to similar levels as found in WT virus infected cells, whereas the 104 
induction of IFN by delNS1 virus was not significantly reduced in these cells. Because of the 105 
limited effect on IFN induction, we then hypothesized that the low yield of delNS1 virus on 106 
normal MDCK cells could be caused by loss of another NS1 regulatory function rather than 107 
the inability of the virus to interfere with the host cells antiviral response. In this paper we 108 
increased the replication efficiency of delNS1 virus by adaptation to IFN competent MDCK 109 
cells during serial passage. Next, we determined if the observed increase in virus yield was 110 
related to decreased IFN and apoptosis induction. Furthermore, we identified the mutations 111 
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and partly characterized the mechanism that allowed the virus to efficiently replicate in the 112 
absence of the NS1 protein.  113 
  114 
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Materials and methods 115 
Cell culture and virus strains 116 
MDCK-SFS (Serum-Free Suspension) cells (47) were grown in suspension in 117 
SFM4BHK21 medium (Hyclone, Waltham, MA), supplemented with 8 mM glutamine, 5 mg/L 118 
phenol red and 1.5 g/L sodium bicarbonate, or adherent in serum-free UltraMDCK medium 119 
(Lonza Biowhittaker, Basel, Switzerland) supplemented with 4 mM glutamine. Adherent 120 
NS1Bon2 MDCK cells (46) were also grown in UltraMDCK medium, additionally 121 
supplemented with 200 μg/ml G418 (Promega, Fitchburg, WI) and 100 μg/ml hygromycin B 122 
(Clontech, Mountain View, CA). G418 and hygromycin were not used during virus infections. 123 
Vero and Human embryo kidney (293T) cells were cultured in Glutamax medium (Invitrogen, 124 
Carlsbad, CA) supplemented with 10% FBS. All culture media were provided with 100 125 
units/ml penicillin and 100 µg/ml streptomycin (Gibco). Cells were grown at 37˚C and 5% 126 
CO2. Suspension cells were grown in shaker flasks at 100 rpm. Cell density and viability were 127 
determined with a Countess automated cell counter (Invitrogen). 128 
All virus strains described in this paper are based on the A/PR/8/34 [H1N1] (PR8) 129 
strain in which the HA and NA genes are replaced by those from A/turkey/Turkey/1/05 130 
H5N1 (46). The multi-basic cleavage site of H5 was replaced by that of a low pathogenic H6 131 
subtype (46) and we refer to this HA gene segment as H5(6). This H5(6)N1 virus (46) strain 132 
containing the complete NS segment was passaged once in 9-day old embryonated eggs 133 
after virus rescue, and is referred to as WT virus. The influenza delNS1 virus strain (46) used 134 
for the adaptation to MDCK-SFS cells is isogenic to WT virus except for the NS gene 135 
segment. It was previously passaged 10 times in 7-day old embryonated chicken eggs and is 136 
referred to as delNS1EA. Note that in the comparison of reassortant virus replication, protein 137 
expression, apoptosis and IFN-induction, a non-adapted delNS1 virus strain was used, to 138 
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which we refer as delNS1. The infectious influenza virus titre was measured by determining 139 
the tissue culture infective dose required to infect 50% (TCID50) of MDCK cells, as previously 140 
described (47). All virus strains were propagated on the NS1 expressing NS1Bon2 MDCK cell 141 
line to generate virus seed stocks with high infectious virus titres (>7 log10 TCID50/ml) prior 142 
to further viral characterization. For this purpose, NS1 expression was induced in this cell 143 
line 24 h before infection by addition of 1 µg/ml doxycycline (Clontech) to the culture 144 
medium, followed by infection at multiplicity of infection (MOI) 0.01 and harvesting at 3 145 
days post-infection (dpi). 146 
 147 
Virus adaptation 148 
Two independent adaptation experiments were performed. In the first experiment, 149 
MDCK-SFS cells in suspension were infected with delNS1EA at MOI 0.1. After 2-3 days the 150 
supernatant was collected and a 500-fold dilution was used for subsequent infection of 151 
fresh MDCK-SFS cells (unknown MOI). The virus was serially passaged 10 times in this 152 
manner. In the second adaptation experiment 5 serial passages were performed, starting 153 
with infection of adherent MDCK-SFS cells with delNS1EA at MOI 0.01. The infectious virus 154 
titre was determined daily and the supernatant with the highest titre was used in 155 
subsequent infection of fresh MDCK-SFS cells at MOI 0.01. The two adapted virus strains 156 
were cloned 3 times by limiting dilution on MDCK-SFS cells. Of each adapted strain, eight 157 
clones were screened for virus replication on MDCK-SFS cells and one clone of each strain 158 
with high titre was selected and amplified on NS1Bon2 cells. The resulting strains are 159 
referred to as delNS1CA1 and delNS1CA2 respectively. 160 
 161 
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Plasmids 162 
Ten plasmids containing single or multiple mutations found in delNS1CA1 and delNS1CA2 163 
(Table 1) were made. Viral RNA of delNS1CA1 and delNS1CA2 was isolated from seed virus and 164 
HA and M gene segments were amplified by PCR, using primers with BsmBI restriction sites 165 
(18). The resulting cDNAs were inserted in plasmid pHW2000 to create pROM33-pROM36. 166 
Plasmids containing the mutated PB1 segments of delNS1CA1 and delNS1CA2 could not be 167 
made. pROM16 was made by cloning a synthetic 675 bp BsrGI-NgoMIV fragment (GenScript 168 
Corporation, Piscataway, NJ) containing mutation A1381G in pHW195 containing the PR8 NP 169 
gene (17). Synthetic fragments with suitable BsmBI restriction sites comprising the complete 170 
M segment with one or more of the CA2 mutations or the complete delNS1 NS segment 171 
with all six CA1 mutations were inserted in pHW2000 to construct pROM13 and pROM51-172 
pROM54. All plasmid inserts were sequenced to ensure the absence of additional nucleotide 173 
substitutions. 174 
 175 
Rescue of recombinant influenza virus 176 
To generate recombinant influenza virus, a mixture of 1.5 x 106 293T and 5 x 105 177 
MDCK-SFS cells were transfected with equal amounts of the eight plasmids containing the 178 
different gene segments, using Fugene HD (Roche Applied Science, Penzberg, Germany). 179 
DelNS1 viruses were made using plasmids pHW191 (GenBank accession no. of vRNA coding 180 
region: AB671295), pHW192 (EF467819), pHW193 (CY058518), pHW195 (EF467822), 181 
pHW197 (EF190985) (17), pPolsaprib H5, pPolsaprib N1 and pHW NEP (46), whereas WT 182 
virus was made by replacing pHW NEP with pHW198, which contains the full length NS 183 
segment. All other recombinant viruses were made by replacing one or more plasmids with 184 
those in Table 1. At 24 h post-transfection (hpt) the transfection mixture was replaced by 185 
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Glutamax medium supplemented with 0.3 % bovine serum albumin (Chemie Brunschwig AG, 186 
Basel, Switzerland) and 1 μg/ml TPCK-trypsin (Sigma-Aldrich, St. Louis, MO). Virus was 187 
harvested at 96 hpt. Virus stocks were generated using NS1Bon2 cells as described above 188 
and virus identity was confirmed by sequence analysis. Reassortant delNS1 virus strains are 189 
referred to as delNS1, followed by the mutated gene segment(s) it contains (Table 1) and 190 
the adapted virus from which they originate (e.g. delNS1:[NP M]CA1, which contains the 191 
mutated NP and M gene segments from delNS1CA1).  192 
 193 
Virus genome sequencing 194 
Viral RNA genomes were isolated using a high pure viral RNA isolation kit (Roche 195 
Applied Science). Universal influenza genome primer uni12 (18) was used for reverse 196 
transcriptase reactions with the Superscript III first strand synthesis system (Invitrogen), 197 
followed by segment specific PCR reactions with an Expanded high fidelity PCR system 198 
(Roche Applied Science). DNA sequencing was performed at Baseclear (Leiden, the 199 
Netherlands) and sequence analysis was done with Lasergene (DNASTAR Inc, WI). 200 
 201 
Comparison of virus replication 202 
To study the infection kinetics of the different virus strains, 106 MDCK-SFS or Vero 203 
cells per well were incubated in 6-well plates, in 5 ml UltraMDCK medium containing 2 204 
µg/ml trypsin-TPCK. Cells were infected in triplicate at MOI 0.01. Because of their ability to 205 
inactivate trypsin (19), Vero cells were supplied with additional trypsin-TPCK (1 µg/ml) at 24 206 
and 48 hour post-infection (hpi). Supernatant was sampled at the indicated intervals and 207 
stored at -80°C before determining the infectious virus titre.  208 
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The main effect and interactions of the mutated gene segments on the infectious 209 
virus titre was analysed by a repeated measures ANOVA with data from two infection 210 
experiments, both performed in triplicate, using R statistical software package (R 211 
Foundation for Statistical Computing, Vienna, Austria). Analysis was performed separately 212 
for delNS1CA1 and delNS1CA2 reassortants datasets, with the mutated gene segments as 213 
explanatory variables, the two infection experiments as random effects and delNS1 virus as 214 
the baseline. Non-significant explanatory variables were excluded from the model. 215 
 216 
IFN reporter assay 217 
MDCK-SFS cells were allowed to attach to the surface of eight 96-well plates for 1 h 218 
(4.5 x 104 cells/well) and then transiently cotransfected with a reporter plasmid carrying a 219 
firefly luciferase gene under control of the IFN-β promoter (p125Luc, kindly provided by 220 
Takashi Fujita, Kyoto University, Japan (54) and a Renilla luciferase control plasmid pGL4.73 221 
(Promega), using Fugene HD. The next day, supernatant was removed and cells were 222 
infected in triplicate (MOI 5) with WT, delNS1, delNS1CA1, delNS1CA2, delNS1:MCA1, 223 
delNS1:MCA2 or delNS1:MCA2.3, or mock infected. One hour later, supernatant was replaced 224 
with fresh medium. At 9, 12, 16, 20 and 24 hpi one plate was stored at -20˚C without 225 
supernatant. The firefly luciferase activity of all plates was measured with a GloMax-Multi 226 
luminometer (Promega) using the Dual Luciferase Reporter Assay System (Promega) and 227 
normalized to the Renilla luciferase activity. 228 
 229 
Apoptosis assay 230 
MDCK-SFS cells were allowed to attach to the surface of six 96-well plates for 1 h (104 231 
cells/well) and infected in sextuple with WT, delNS1, delNS1CA1 or delNS1CA2 virus (MOI 5), 232 
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or mock infected. One hour later, supernatant was replaced with fresh medium. At 10, 14, 233 
16, 19, 22 and 26 hpi, one plate was stored at -20˚C without supernatant. Apoptosis was 234 
determined by the activity of caspase-3 and caspase-7 using Caspase-Glo 3/7 Assay 235 
(Promega). Caspase-Glo reagent, diluted 1:1 with PBS, was added to the frozen cells (50 236 
μl/well). After 1.5 h incubation at room temperature, the luminescence was measured with 237 
a GloMax-Multi luminometer.  238 
 239 
Western blot analysis of M1 and M2 expression 240 
MDCK-SFS cells were allowed to attach to the surface of 24-well plates for 1 h (3.3 x 241 
105 cells/well) and infected (MOI 5) or mock infected, in triplicate. HEK293T cells (106 242 
cells/well in 6-well plates) were transiently transfected in triplicate, using Fugene HD with 243 
either 2 µg/well pHW195, pROM35, pROM36, pROM51, pROM52, pROM53, pROM54 (Table 244 
1) or mock transfected. At 10 hpi or 48 hpt, cells were lysed with reducing NuPAGE sample 245 
buffer containing in addition complete EDTA-free protease inhibitor cocktail (Roche). 246 
Samples were sheared with a 21G needle, incubated for 10 min at 75°C and loaded onto 247 
NuPAGE® Novex® 12% Bis-Tris precast gels (Invitrogen). Polypeptides were transferred to 248 
polyvinylidenedifluoride membranes and detected by immunoblotting using monoclonal 249 
mouse antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) against M1 (SC-57881, 0.2 250 
µg/ml) or M2 (SC-32238, 0.4 µg/ml). After subsequent incubation with peroxidase-251 
conjugated rabbit anti-mouse immunoglobulins (0.13 µg/ml; Dako, Glostrup, Denmark), 252 
proteins were visualized with ECL plus (GE Healthcare, Buckinghamshire, UK) and quantified 253 
with a Storm840 imaging system and ImageQuant software (Molecular Dynamics, 254 
Sunnyvale, CA). The M1/M2 band intensity ratio of each sample was calculated before 255 
determining the mean ratio of the triplicate infections or transfections.  256 
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 257 
Subcellular M1 localization 258 
MDCK-SFS cells were cultured in suspension (6.6 x 105 cells/ml) and infected with 259 
WT, delNS1 or delNS1:MCA2.3 in triplicate (MOI 5). At 6 and 10 hpi, 106 cells were harvested 260 
and cytoplasmic and nuclear extracts were prepared with the NE-PER nuclear and 261 
cytoplasmic extraction kit (Thermo Fisher Scientific, Rockford, IL), according to the 262 
manufacturer’s description. However, complete EDTA-free protease inhibitor cocktail was 263 
added to the extraction reagents. Cytoplasmic and nuclear extractions were subjected to 264 
reducing SDS-PAGE and Western blot analysis as described above. Polypeptides were 265 
detected by immunoblotting as described in the previous section with monoclonal mouse 266 
antibodies (Santa Cruz Biotechnology) against lamin A/C (SC-7292, 0.2 µg/ml), tubulin (SC-267 
5286, 0.2 µg/ml) or M1 (SC-57881, 0.2 µg/ml). Cytoplasmic and nuclear specific proteins 268 
tubulin and lamin A/C were used to assess the purity of nuclear and cytoplasmic extracts. 269 
The amount of M1 protein was corrected for the extraction efficiency by either tubulin 270 
(cytoplasmic extracts) or lamin A/C (nuclear extracts). The ratio of corrected nuclear M1 to 271 
corrected cytoplasmic M1 was calculated before determining the mean ratio of the 272 
triplicate infections. 273 
  274 
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Results 275 
delNS1 virus adaptation 276 
The egg-adapted influenza virus delNS1EA replicated poorly in MDCK cells, reaching a 277 
maximum infectious virus titre that was 104-fold lower than that of WT virus (Fig. 1B). To 278 
investigate whether the virus was able to overcome the negative effect of the NS1 deletion 279 
by acquiring compensating mutations we serially passaged delNS1EA virus on MDCK-SFS cells 280 
in two independent adaptation experiments (see Materials and Methods). In the first cell 281 
adaptation experiment (CA1), virus was blindly passaged 10 times. In the second experiment 282 
(CA2), virus taken from the time point where the titre was maximal was used to infect cells 283 
in the next passage at a controlled MOI of 0.01. Both adaptation experiments on MDCK-SFS 284 
cells resulted in virus populations with increased replication rate and increased maximum 285 
titres compared to the parent strain. The maximum virus titre of strain delNS1CA2 increased 286 
during the first 3 to 4 passages, but did not increase further during the fifth passage (Fig. 287 
1A). To obtain clonal virus, the adapted strains were further cultured during 3 limiting 288 
dilution steps on MDCK-SFS cells. The infectious virus titres of the resulting cloned cell-289 
adapted virus strains delNS1CA1 and delNS1CA2 were about 250-fold higher than the parental 290 
delNS1EA virus titre, but remained 25-fold lower than the WT virus titre (Fig. 1B). In Vero 291 
cells, delNS1EA was only weakly attenuated in comparison to the WT virus (Fig. 1C). 292 
Adaptation of delNS1 virus to MDCK-SFS cells caused only a small increase in delNS1CA2 virus 293 
replication in Vero cells whereas delNS1CA1 virus replication was comparable to the parental 294 
delNS1 virus (Fig. 1C). Thus, the increase in virus replication due to virus adaptation is much 295 
higher during propagation on MDCK-SFS cells as compared to Vero cells.  296 
 297 
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Sequence analysis of adapted virus 298 
 All eight gene segments of the delNS1CA1 and delNS1CA2 virus strains and their 299 
parental delNS1EA strain were sequenced (Table 2). No mutations were found in the PB2, PA 300 
and NA segments. The delNS1EA virus contained two mutations in PB1 and one in HA with all 301 
mutations present in approximately 50% of the virus population. These mutations were 302 
silent and must have arisen during the passaging in eggs. Both PB1 mutations were present 303 
in both cell adapted viruses, whereas the HA mutation was only present in delNS1CA2 virus. 304 
Due to the presence of mutations in the delNS1EA virus, a non-adapted delNS1 virus was 305 
used in the comparison of reassortant virus replication, protein expression, apoptosis, and 306 
IFN-induction experiments. We refer to this virus as delNS1. 307 
Compared to delNS1EA virus, delNS1CA1 virus had 13 additional mutations, including a 308 
silent mutation in PB1, F257L in HA, R446G in NP, four silent U-to-C mutations in M, and six 309 
A-to-G mutations in the delNS1 segment. Three of the NS segment mutations resulted in the 310 
amino acid substitutions Y41C, M52V and I76V in the NEP protein. The first 4 A-to-G 311 
mutations in the NSCA1 segment are located on the part that normally encodes NS1, 312 
resulting in two amino acid substitutions at the NS1 C-terminal. These mutations may be 313 
disadvantageous to the WT virus and removal of the NS1 ORF therefore increased the 314 
freedom of this segment to acquire mutations. DelNS1CA2 virus had 6 additional mutations 315 
that were all located in the M segment. These mutations started to appear simultaneously 316 
at passage 4 and had increased at passage 5 (Fig. 2A). Again, these 6 mutations were all U-317 
to-C mutations, two of which resulted in amino acid changes V97A and Y100H in M1. 318 
Notably, all mutations on the M and NS segments are clustered in regions of 50-100 319 
nucleotides. Both M segment mutation clusters are located on a region of the M1 mRNA 320 
that is removed by splicing to generate the M2 mRNA and thus do not affect M2 mRNA 321 
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structure (Fig. 2B). Apart from the two silent mutations in PB1 which were already present 322 
in the initial delNS1EA virus, both parallel adaptations did not lead to identical mutations. 323 
 324 
Infection with delNS1 viruses containing mutated gene segments 325 
The effect of each mutated gene segment on the infectious virus titre, and possible 326 
interactions between the gene segments was determined by employing a full-factorial 327 
analytical approach. MDCK-SFS cells were infected with reassortant delNS1 viruses 328 
consisting of all 15 possible combinations of delNS1CA1 virus HA, NP, M and NS gene 329 
segments, or the 3 possible combinations of delNS1CA2 virus HA and M gene segments (Fig. 330 
3A). All reassortant viruses contained the WT PB1 segment, as we were unable to generate 331 
plasmids containing the mutated PB1 segments. Infectious virus titres were examined using 332 
a repeated measures ANOVA, so as to determine the relative importance of the gene 333 
segments, and possible interactions between gene segments, on virus replication. Segments 334 
with significant effect on the delNS1CA1 virus titre were NSCA1, MCA1 and NPCA1, with 335 
coefficients of respectively 0.68, 0.76 and 0.50 (all p<0.001). These coefficients specify the 336 
average increase of the virus titre in log10 TCID50/ml, when the mutated segment was 337 
included in the delNS1 reassortant strain. There was also an interaction effect between the 338 
mutated M and NP segments of -0.36 (p<0.05), which indicated an average decrease in virus 339 
titre when the mutated M and NP segments were combined in the delNS1 virus. Thus, the 340 
enhanced delNS1CA1 virus replication was the effect of these three mutated gene segments 341 
together. The enhanced replication of delNS1CA2 was determined by the mutated M 342 
segment alone (Fig. 3A). This observation was confirmed by statistical analysis, which 343 
appointed a coefficient of 2.0 (p<0.001) to MCA2, indicating that the 100-fold increase in 344 
virus titre was solely determined by the M segment mutations. Reassortant virus containing 345 
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all mutated gene segments (delNS1:[HA NP M NS]CA1 and delNS1:[HA M]CA2) replicated 346 
equally well as the virus from which their segments originated, delNS1CA1 and delNS1CA2, 347 
indicating that the mutated PB1 gene segments did not contribute to the enhanced virus 348 
replication. 349 
Because the M segment plays a major role in increased replication of both adapted 350 
viruses, we further focused on the mechanism by which mutations in this segment could 351 
overcome the decreased replication in the absence of NS1. To determine which individual 352 
MCA2 mutation was responsible for virus titre increase, four additional mutant virus strains 353 
were made containing either the V97A or Y100H mutation, the combination of V97A and 354 
Y100H, or the remaining four silent mutations (Fig. 3B). When compared to delNS1, the two 355 
strains with single amino acid substitutions did not replicate more efficiently. However, 356 
when V97A and Y100H were combined in delNS1:MCA2.3, a 50-fold increase in virus titre was 357 
observed. Furthermore, the four silent mutations increased the virus yield approximately 358 
10-fold, as indicated by the comparison of delNS1 to delNS1:MCA2.4 and delNS1:MCA2.3 to 359 
delNS1CA2. Interestingly, when introduced into the WT virus, the MCA2 segment decreased 360 
replication (Fig. 3B).  361 
 362 
Interferon-β and apoptosis induction by cell adapted delNS1 virus 363 
To assess if viral adaptation affected IFN-β expression, cells were transfected with a 364 
firefly luciferase reporter gene under control of an IFN-β promoter and subsequently 365 
infected with WT or different delNS1 virus strains at high MOI. The low luciferase activity of 366 
cells infected with WT virus as compared to cells infected with delNS1 virus indicates 367 
inhibition of IFN-β induction by NS1 (Fig. 4A). Both cell-adapted viruses (Fig. 4A) as well as 368 
delNS1 reassortant virus containing either MCA1, MCA2 or the M segment containing the two 369 
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CA2 amino acid mutations (Fig. 4B) did not show lower IFN induction than parental delNS1 370 
virus (Fig. 4A). This indicates that the increase in virus replication due to virus adaptation 371 
was not caused by a lower IFN induction.  372 
The induction of apoptosis was determined by measuring the activity of caspase-3 373 
and caspase-7, two proteases that are induced late in the apoptosis pathway. Again, the 374 
inhibiting effect of NS1 was visible as little caspase activity was seen in cells infected with 375 
the WT virus in comparison to cells infected with delNS1 viruses. Both cell-adapted 376 
delNS1CA1 and delNS1CA2 viruses similarly induced caspase activity to a level that is far higher 377 
than observed with WT virus (Fig. 4C). 378 
 379 
Effect of M segment mutations on M1 and M2 protein expression 380 
To determine if the M segment mutations affected splicing of the M1 mRNA (Fig. 2B) 381 
we measured the ratio of M1 and M2 protein expression in cells at 10 hpi by Western blot 382 
analysis (Fig. 5A). The M1 protein of all Y100H mutant viruses (delNS1:MCA2, delNS1:MCA2.2 383 
and delNS1:MCA2.3) migrated slightly slower in SDS-PAGE than that of the other virus strains 384 
(Fig. 5A, lanes 4, 6 and 7 respectively). Slight changes in mobility in SDS-PAGE due to amino 385 
acid changes that affect protein charge, such as Y100H, have been observed before (30). 386 
Cells infected with delNS1 virus (Fig. 5A, lane 2) appeared to express more M2 387 
protein than WT virus infected cells (Fig. 5A, lane 1). This difference was consistently 388 
observed in several experiments, even though the difference in M1/M2 ratio was not 389 
statistically significant from that of the WT virus (Fig. 5B). Infection with virus containing the 390 
mutated M segments, delNS1:MCA1 (Fig. 5A, lane 3) and MCA2 (Fig. 5A, lane 4), resulted in an 391 
M1/M2 ratio that was 2- and 3-fold higher, respectively, than that of delNS1 (Fig. 5B). Virus 392 
containing only the single or double M1 amino acid mutations (delNS1:MCA2.1, MCA2.2 and 393 
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MCA2.3, Fig. 5A lanes 5, 6 and 7) showed an M1/M2 ratio similar to delNS1, whereas 394 
delNS1:MCA2.4 virus (containing the 4 silent MCA2 mutations) showed a 2-fold increase (Fig. 395 
5A lane 8 and Fig. 5B). The effect of the mutations on M1 and M2 expression was confirmed 396 
by transfection of HEK293T cells with plasmids encoding the different M segments (Fig. 5C). 397 
The M1/M2 ratio of cells transfected with WT M segment (0.35; Fig. 5D), is comparable to 398 
that of delNS1 infected cells (0.42; Fig. 5B). The M1/M2 expression ratio was higher with 399 
segments containing the original mutations acquired during the adaptation (MCA1 and MCA2) 400 
and with the MCA2 segment containing the four silent mutations (MCA2.4; Fig. 5C lanes 3, 4 401 
and 8), but not with the MCA2 segments containing one or both of the non-silent mutations 402 
(Fig. 5C lane 5, 6 and 7). Taken together, these results show that both cell-adapted viruses 403 
acquired mutations that increased the M1/M2 protein ratio in infected cells. 404 
 405 
Effect of M1 amino acid substitutions on subcellular localization 406 
 The M1 mutations V97A and Y100H present in delNS1CA2 are located close to the NLS 407 
at position 101-105 (Fig. 2C). To determine whether they affected the subcellular 408 
localization of M1 protein, cells were infected with WT, delNS1 or delNS1:MCA2.3 virus and 409 
the nucleoplasm and cytoplasm was isolated early (6 hpi) and late (10 hpi) in the infection 410 
process. The level of M1 present in both compartments was then determined by Western 411 
blot analysis and quantified by phosphorimager densitometry (Fig. 6A and B). 412 
At 6 hpi, the ratio of nuclear to cytoplasmic M1 was comparable between WT and 413 
delNS1 virus infected cells (Fig. 6B). Four hours later, this ratio remained constant in WT 414 
virus infected cells whereas it was 4-fold lower in delNS1 virus infected cells, mainly due to a 415 
decrease in nuclear M1. Thus, NS1 appears to affect the concentration of M1 in the nucleus 416 
late but not early in the infection. The mutant virus containing only M1 amino acid 417 
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substitutions V97A and Y100H showed a higher ratio at early stages, although this did not 418 
significantly differ from the ratio of the other two viruses. At 10 hpi nuclear M1 was not 419 
detectable anymore, thereby reducing the localization ratio below that of delNS1 infected 420 
cells. 421 
  422 
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Discussion 423 
The low yield of delNS1 virus on MDCK cells is assumed to be caused by the inability 424 
of this virus to inhibit the antiviral host response (14). In this study, we obtained two delNS1 425 
influenza virus variants that replicated to 250-fold higher infectious virus titres (TCID50) after 426 
two parallel, serial passages on MDCK cells. However, the increase in virus replication did 427 
not correlate with a lower induction of IFN or apoptosis, which is linked to IFN induction (4, 428 
44, 57). These results thus indicate that IFN induction may not be the only cause of limited 429 
delNS1 virus replication in MDCK cells. Several recent studies already suggest that IFN has a 430 
minor effect on influenza replication in MDCK cells because canine myxovirus resistance 431 
proteins lack anti-influenza activity (38) and secreted IFN is proteolytically degraded by 432 
trypsin, which is normally present during influenza production on MDCK cells (39). 433 
Furthermore, delNS1 virus titres could be increased by recombinant NS1 expression, 434 
without lowering IFN induction (46), indicating that IFN induction in MDCK may play a less 435 
important role than generally assumed. 436 
The two adapted viruses contained a high frequency of either A-to-G or U-to-C 437 
substitutions (19 out of 22) that occur mostly (16 out of 22) in three clusters in MCA1, MCA2 438 
and NSCA1 gene segments. Furthermore, all mutations in MCA2 appeared to be acquired at 439 
the same time. Taken together, this suggests that these substitutions result from 440 
hyperediting by adenosine deaminases acting on RNA (ADAR), which cause A-to-G 441 
substitutions in RNA (37). Hyperediting of the influenza genome by ADAR has previously 442 
been reported (42). The occurrence of both A-to-G and U-to-C substitutions can be 443 
explained by hyperediting of the positive sense cRNA as well as the negative sense vRNA, 444 
respectively. Interestingly, ADAR1 is induced by IFN and is believed to have an antiviral role 445 
during influenza infection (37). Furthermore, NS1 interacts with ADAR1, suggesting that it 446 
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inhibits ADAR1 function (28). Possibly, the high level of IFN induction and the absence of 447 
NS1 in delNS1 infected cells resulted in more RNA hyperediting.  448 
By sequence analysis of the two adapted viruses and subsequent analysis of 449 
reassortant viruses generated by reverse genetics, we showed that six substitutions in the M 450 
segment were responsible for the increase in delNS1CA2 virus titres. The increase in 451 
delNS1CA1 viral titres was caused by substitutions in the NP, M and NS segments, where the 452 
M segment was most important. Previously, adaptation to Vero cells yielded an influenza B 453 
delNS1 virus with increased titres due to M1 amino acid substitution M86V (51). This is in 454 
striking contrast to the many studies on the adaptation of WT virus originating from eggs or 455 
clinical specimens to propagation in mammalian hosts or cell lines, which showed that 456 
adaptive mutations predominantly accumulated in the HA segment or segments encoding 457 
the RNA polymerase (PB1, PB2 and PA), which is assumed to be caused by adaptation to the 458 
different host species (16, 29, 34, 45). This suggests that the preferential isolation of M-459 
segment mutations upon delNS1 virus adaptation compensates for the absence of the NS1 460 
protein rather than the replication in a different host species. This conclusion is further 461 
supported by our observation that the introduction of the MCA2 gene segment into a WT 462 
virus (that produces NS1) does not enhance, but even reduces, viral replication.  463 
Therefore, we focused on the mechanism by which the M segment mutations could 464 
improve replication in the absence of NS1. The M segment encodes the M1 matrix protein 465 
from unspliced M1 mRNA, whereas the M2 ion channel protein is transcribed from a spliced 466 
mRNA (Fig. 2B). A second splice product, mRNA3, can arise from an alternative 5’ splice site 467 
and encodes a hypothetical and as yet undiscovered 9 amino acid peptide (21). It was 468 
previously shown that NS1 expression limits splicing, including that of the M segment-469 
derived mRNA (23, 32), resulting in a higher ratio of M1 to M2 mRNA. Furthermore, M1 470 
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expression is reduced in MDCK cells infected with influenza virus expressing truncated NS1 471 
(8, 10). We therefore measured M1 and M2 expression in infected cells and calculated the 472 
M1/M2 expression ratio, assuming that this would be dependent on the efficiency of M1 473 
mRNA splicing. Indeed, cells infected with WT virus showed a higher M1/M2 expression 474 
ratio than delNS1 infected cells. The MCA1 and MCA2 segments showed significantly increased 475 
M1/M2 expression ratios as compared to the WT M segment, both when expressed using a 476 
delNS1 virus backbone and after transfection of cells with M gene-encoding plasmids. The 477 
MCA1 segment contains four silent mutations whereas the MCA2 segment contains four silent 478 
and two non-silent mutations. By generating novel reassortant viruses we could show that 479 
the altered M1/M2 expression ratio of delNS1CA2 was due to the 4 silent mutations. 480 
Furthermore, these silent MCA2 mutations caused an increase in delNS1 viral titres, although 481 
not to the same extent as a segment that also contains the two non-silent M segment 482 
mutations. The silent MCA1 and MCA2 mutations lay in a region that contains the major 483 
determinants for M segment splicing (3). Thus it is likely that both these sets of mutations 484 
lower M1 mRNA splicing efficiency in a similar manner by restoring a balance that was 485 
disturbed due to the absence of NS1. Such a mechanism, aimed at restoration of M1 splicing 486 
efficiency may also explain why introduction of the MCA2 segment into a backbone of virus 487 
that produces NS1 (WT virus) reduces replication efficiency. Surprisingly, NS1 does not 488 
affect the M1/M2 expression ratio in Vero cells (36). Furthermore, absence of NS1 causes 489 
reduced M1 expression in MDCK but not in Vero cells (8). Taken together with our results 490 
this suggests that the improved replication of delNS1 virus in Vero cells as compared to 491 
MDCK cells is not only determined by the lack of an IFN response, but also by the ability of 492 
Vero cells to retain efficient M segment splicing and M1 expression in the absence of NS1. 493 
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The major part of the increase in delNS1CA2 virus titre resulted from the combination 494 
of M1 amino acid substitutions V97A and Y100H. As single substitutions these mutations did 495 
not affect replication efficiency. Mutation V97A was previously introduced into the 496 
A/WSN/33 [H1N1] strain (which is able to express NS1) and resulted in a 100-fold lower 497 
virus yield (6). Residues 97 and 100 are located on the helix 6 (H6) domain, a positively 498 
charged surface region between amino acids 91 to 105 of M1 (40). The influenza B M1 499 
M86V mutation that enhanced delNS1 virus replication (51) is located near this region. The 500 
exact mechanism by which this mutation affected viral replication was not further 501 
investigated. The H6 domain has multiple functional motifs, including a nuclear localization 502 
signal (NLS) between amino acids 101-105 (Fig. 2C) that binds to cellular importin-α (5). 503 
Inside the nucleus, M1 binds to the vRNP complex, after which NEP can bind to the NLS of 504 
M1 (1). The vRNP-M1-NEP complex can then be exported to the cytoplasm were virus 505 
particles are assembled at the cell membrane (1). The localization of V97A and Y100H within 506 
the H6 domain suggests that they could affect M1 binding to NEP. Furthermore, Y100H is 507 
located immediately next to the NLS and may also affect importin-α binding, as described 508 
earlier for a mutation next to a NLS in PB2 (29). In this manner these mutations could affect 509 
M1 (and vRNP) subcellular distribution. The absence of NS1 during infection resulted in 510 
decreased levels of M1 in the nucleus at late stages of the infection. This may result from 511 
increased apoptosis induction by delNS1 virus as widening of the nuclear pores (11) allows 512 
diffusion of vRNPs out of the nucleus (24). Amino acid changes V97A and Y100H resulted in 513 
full depletion of M1 in the nucleus at 10 hpi, thus these mutations do not restore the M1 514 
localization balance in delNS1 towards infection in the presence of NS1. It is therefore 515 
difficult to speculate how these two mutations can cause a 50-fold increase in virus titre.  516 
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Interestingly, the increased viral titres of delNS1CA1 virus were in part due to six 517 
nucleotide substitutions causing three amino acid substitutions in the NEP protein. 518 
Especially substitution I76V which is located within the domain that binds to M1 (1) could - 519 
similarly to the M1 mutations described above - affect vRNP nuclear export. Similar effects 520 
of M1 and NEP mutations that affect their interaction were observed earlier in WT virus. 521 
Mutations of NEP glutamate residues 67, 74 and 75 that bind M1, decreased vRNP content 522 
of viral particles and caused morphological virion changes similar to those that occur in virus 523 
particles with mutated positively charged M1 residues 95, 98, 101 and 102 that bind NEP (2, 524 
6).  525 
In this paper we showed that mutations in the M segment can enhance the 526 
replication of delNS1 virus due to both non-silent and silent mutations, the latter 527 
presumably affecting the M1 mRNA splicing efficiency. These findings contradict the 528 
previous suggestion that the restricted replication of this virus in MDCK cells is primarily due 529 
to the inability to inhibit the IFN response. The mutations described may have direct 530 
applications as they, for example, allow the development of delNS1 based viruses with 531 
improved replication efficiency, thereby making it possible to produce such a virus in other 532 
cell lines than Vero cells (35) or NS1 expressing MDCK cells (46). Moreover, these mutations 533 
may be combined with the G3A and C8U mutations in HA vRNA, which increased the HA 534 
expression level of a live attenuated NS1 truncated influenza vaccine strain (25). However, it 535 
will be necessary to determine the effect of these mutations on vaccine safety and efficacy. 536 
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Figure legends 726 
Fig. 1. Replication of delNS1 virus adapted to growth on MDCK-SFS cells. Maximum 727 
infectious virus titre during each passage step of the second delNS1 adaptation experiment 728 
(A). Replication kinetics of the two adapted delNS1CA1 and delNS1CA2 virus strains in 729 
comparison to WT and parental delNS1EA virus after infection of MDCK-SFS (B) or Vero (C) 730 
cells at MOI 0.01. Geometric mean titres and 95% confidence interval of the mean of virus 731 
infections performed in triplicate are presented.  732 
 733 
Fig. 2. Nucleotide substitutions in M-gene segments of adapted delNS1 viruses. (A) 734 
Sequence analysis of delNS1CA2 showing the simultaneous accumulation of six U-to-C 735 
substitutions (indicated by arrows) in the M segment vRNA between position 277-325 from 736 
passages 3 to 5 on MDCK-SFS cells. Double peaks are visible at passage 4 and 5. Note that in 737 
the electropherograms U is shown as T. (B) Schematic overview of the M segment mRNAs, 738 
with the locations of the adaptive MCA1 and MCA2 mutations and splicing products M2 mRNA 739 
and mRNA3. Open reading frames are indicated by thick bars. (C) Nucleotide sequences of 740 
the MCA1 and MCA2 regions shown in panel B, including the amino acid sequence of MCA2, 741 
where dots indicate sequence identity of M1CA2 to M1WT. The square box indicates the 742 
location of the NLS in M1, with positively charged (+) amino acids (53). The arrow indicates 743 
the location of the adaptive mutation in influenza B M1 protein found earlier (51). The 744 
amino acid sequence of M1CA1 is not shown since it is identical to M1WT (i.e. all mutations 745 
were silent). 746 
 747 
Fig. 3. Comparison of infectious virus titres 3 d after infection of MDCK-SFS cells with the 748 
cell-adapted or the various reassortant virus strains (MOI 0.01). (A) Titres of delNS1 749 
 36 
 
reassortant viruses made with original delNS1 plasmids (not-filled), or plasmids containing 750 
single or multiple mutations originating from the adapted virus strains delNS1CA1 (filled, 751 
marked 1) and delNS1CA2 (filled, marked 2). (B) Titres of delNS1 reassortant viruses 752 
containing one or more of the delNS1CA2 M segment mutations and of WT reassortant virus 753 
containing the MCA2 mutations. In both panels, geometric mean titres and 95% confidence 754 
interval of the mean are presented of triplicate measurements. 755 
 756 
Fig. 4. Effect of delNS1 virus adaptation on IFN-β and apoptosis induction. IFN induction in 757 
MDCK-SFS cells infected with either WT, delNS1, delNS1CA1 or delNS1CA2 virus, or mock 758 
infected (A), and delNS1:MCA1, delNS1:MCA2 or delNS1:MCA2.3 virus (B) was measured with an 759 
IFN-β dependent luciferase reporter construct and corrected for transfection efficiency with 760 
Renilla luciferase. (C) Induction of apoptosis in MDCK-SFS cells infected with either WT, 761 
delNS1, delNS1CA1 or delNS1CA2 virus, or mock infected. Apoptosis induction was assessed by 762 
measuring the activity of caspase 3 and 7. Geometric mean activities and 95% confidence 763 
interval of the mean are presented of experiment performed in triplicate. 764 
 765 
Fig. 5. Western blot analysis of M1 and M2 protein expression 10 h after infection of MDCK-766 
SFS cells (A) or 48 h after transient transfection of HEK293T cells (C) with plasmid (Table 1) 767 
containing either the WT M segment (pHW197), the mutated MCA1 or MCA2 segments 768 
(pROM36 and pROM35), or the M segment containing one or more delNS1CA2 mutations 769 
(pROM51-54). M1 and M2 protein levels of three independent experiments were quantified 770 
using phosphorimager densitometry. The M1/M2 ratio for each virus (B) or plasmid (D) is 771 
shown as the mean and 95% confidence interval of the mean. Lanes 1-4 and lanes 5-8 in 772 
panel A originated from two different blots. 773 
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 774 
Fig. 6. Subcellular localization of M1 protein. MDCK-SFS cells were infected with WT, delNS1 775 
and delNS1:MCA2.3 virus at high MOI in triplicate. Then, cytoplasm and nucleoplasm fractions 776 
were prepared at 6 hpi and 10 hpi and M1 protein was quantified by Western blot analysis. 777 
Panel (A) shows one representative Western blot. Tubulin (Tub) and lamin A/C (Lam) were 778 
used as cytoplasm and nucleoplasm specific controls, respectively. The isolations were 779 
successful as no tubulin was observed in the nucleoplasm isolates (lane 1-6) and no lamin 780 
A/C was observed in the cytoplasm isolates (lane 8-13). The cytoplasmic isolate of WT virus 781 
at 6 hpi was used as a source of tubulin in lane 7 whereas the nucleoplasmic isolate of WT 782 
virus at 6 hpi was used as a source of lamin A/C in lane 14. Nuclear isolates show aspecific 783 
staining by the tubulin antibody (lane 1-6), which is not present in the cytoplasmic control 784 
(lane 7). (B) M1 protein levels were quantified by phosphorimager densitometry using 785 
tubulin and lamin A/C, respectively, as controls to compensate for the isolation efficiency. 786 
The ratio of corrected nuclear M1 (M1n) to corrected cytoplasmic M1 (M1c) was used to 787 
determine changes in the distribution of M1 and is shown as the mean and 95% confidence 788 
interval of the mean at 6 hpi (empty bars) and 10 hpi (filled bars).  789 
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Tables: 791 
Table 1. pHW2000-derived plasmids encoding mutant gene segments from cell-adapted 792 
delNS1 viruses. 793 
Plasmid Segment  Nucleotide substitutions Amino acid 
substitutionsa 
pROM34 HACA1 U796C F257L 
pROM33 HACA2 C1326A None 
pROM16 NPCA1 A1381G R446G 
pROM36 MCA1 U640C, U643C, U652C, U688C None 
pROM35 MCA2 U277C, U298C, U315C, U316C, U323C, U325C V97A, Y100H 
pROM51 MCA2.1 U315C V97A 
pROM52 MCA2.2 U323C Y100H 
pROM53 MCA2.3 U315C, U323C V97A, Y100H 
pROM54 MCA2.4 U277C, U298C, U316C, U325C None 
pROM13 NSCA1 A148G, A173G, A179G, A180G, A248G, A252G Y41C, M52V, I76V 
a Amino acid positions are relative to methionine in the open reading frame. 794 
 795 
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Table 2. Mutations in egg adapted delNS1EA and cell adapted delNS1CA1 and delNS1CA2 virus 797 
strains. 798 
Gene 
segment 
Nucleotide 
positiona 
Nucleotide substitutionb Amino acid 
substitution b delNS1EA delNS1CA1 delNS1CA2 
PB1 (S2) 798 - G to U - - 
1953 A to U 50%c A to U A to U -
2133 U to C 50%c U to C U to C -
      
HA (S4) 796 - U to C - F257L 
1326 (1338) C to A 50%c - C to A - 
      
NP (S5) 1381 - A to G - R446G 
      
M (S7) 277 - - U to C - 
298 - - U to C - 
315 - - U to C V97A 
316 - - U to C - 
323 - - U to C Y100H 
325 - - U to C - 
640 - U to C - - 
643 - U to C - - 
652 - U to C - - 
688 - U to C - - 
      
NS (S8) 148 (620) - A to G - Y41C 
173 (645) - A to G - - 
179 (651) - A to G - - 
180 (652) - A to G - M52V 
248 (720) - A to G - - 
252 (724) - A to G - I76V 
a Numbering refers to nucleotide positions in the vRNA template [GenBank accession no: 799 
EF467819 (PB1), DQ407519 (HA), EF467822 (NP), EF190985 (M), AF389122 (NS)]. Note that 800 
the numbering of the HA and NS mutations refers to the recombinant gene segments (46). 801 
The numbering in line with the Genbank sequences is placed between brackets. 802 
b Substitutions as compared to sequence of plasmid used for initial delNS1 virus generation. 803 
– No substitution. 804 
c Presence of a second nucleotide sequence within the seed virus. 805 
 806 
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